FI4259632T3 - N-(imidatso[1,2-b]pyridatsin-3-yyli)-1-sykloheksyyli-2h-indatsoli-5-karboksamidi- ja n-(pyratsolo[1,5-a]pyrimidin-3-yyli)-1-sykloheksyyli-2h-indatsoli-5-karboksamidijohdannaisia irak4-estäjinä astman hoitoon - Google Patents
N-(imidatso[1,2-b]pyridatsin-3-yyli)-1-sykloheksyyli-2h-indatsoli-5-karboksamidi- ja n-(pyratsolo[1,5-a]pyrimidin-3-yyli)-1-sykloheksyyli-2h-indatsoli-5-karboksamidijohdannaisia irak4-estäjinä astman hoitoon Download PDFInfo
- Publication number
- FI4259632T3 FI4259632T3 FIEP21836097.2T FI21836097T FI4259632T3 FI 4259632 T3 FI4259632 T3 FI 4259632T3 FI 21836097 T FI21836097 T FI 21836097T FI 4259632 T3 FI4259632 T3 FI 4259632T3
- Authority
- FI
- Finland
- Prior art keywords
- cyclohexyl
- carboxamide
- indazole
- methoxy
- pyrazolo
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title claims 3
- 229940127590 IRAK4 inhibitor Drugs 0.000 title 1
- SLFYLMUBNWHOSJ-UHFFFAOYSA-N O=C(C1=CC=C2N(C3CCCCC3)NCC2=C1)NC1=CN=C2N1N=CC=C2 Chemical compound O=C(C1=CC=C2N(C3CCCCC3)NCC2=C1)NC1=CN=C2N1N=CC=C2 SLFYLMUBNWHOSJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 14
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- -1 (1-pyrimidin-3-yl)-2H-indazole-5-carboxamide Chemical compound 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 1
- 101100440696 Caenorhabditis elegans cor-1 gene Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002774 Paraproteinemias Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063199160P | 2020-12-10 | 2020-12-10 | |
| PCT/EP2021/084916 WO2022122876A1 (en) | 2020-12-10 | 2021-12-09 | N-(imidazo[1,2-b]pyridazin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide and n-(pyrazolo[1,5-a]pyrimidin-3-yl)-1-cyclohexyl-2h-indazole-5-carboxamide derivatives as irak4 inhibitors for the treatment of asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4259632T3 true FI4259632T3 (fi) | 2024-10-24 |
Family
ID=79230946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21836097.2T FI4259632T3 (fi) | 2020-12-10 | 2021-12-09 | N-(imidatso[1,2-b]pyridatsin-3-yyli)-1-sykloheksyyli-2h-indatsoli-5-karboksamidi- ja n-(pyratsolo[1,5-a]pyrimidin-3-yyli)-1-sykloheksyyli-2h-indatsoli-5-karboksamidijohdannaisia irak4-estäjinä astman hoitoon |
Country Status (33)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023152349A1 (en) * | 2022-02-14 | 2023-08-17 | Astrazeneca Ab | Irak4 inhibitors |
| US20250326757A1 (en) * | 2022-05-26 | 2025-10-23 | Astrazeneca Ab | Solid forms of heterocyclylamides as irak4 inhibitors |
| US20240374588A1 (en) | 2023-04-07 | 2024-11-14 | Astrazeneca Ab | Irak4 protacs |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4モジュレーターとしてのピラゾロ[1,5a]ピリミジン及びチエノ[3,2b]ピリミジン誘導体 |
| HUE029617T2 (en) | 2010-12-20 | 2017-03-28 | Merck Serono Sa | Indazolyl triazole derivatives as IRAK inhibitors |
| BG111378A (bg) * | 2013-01-14 | 2015-01-30 | Николай Цветков | Субституирани индазолови производни като in-vitro mao-b инхибитори |
| RU2665554C2 (ru) * | 2013-03-15 | 2018-08-31 | Байомарин Фармасьютикал Инк. | Ингибиторы hdac |
| HK1231480A1 (zh) | 2014-01-10 | 2017-12-22 | Aurigene Discovery Technologies Limited | 作为irak4抑制剂的吲唑化合物 |
| PL3536685T3 (pl) | 2014-04-04 | 2022-05-16 | Pfizer Inc. | Bicykliczne skondensowane związki heteroarylowe lub arylowe i ich zastosowanie jako inhibitory IRAK4 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
| CA2992406A1 (en) | 2015-07-15 | 2017-01-19 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as irak-4 inhibitors |
| EP3322409A4 (en) | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS |
| CN105503863A (zh) * | 2015-12-11 | 2016-04-20 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
| EP3394066A2 (en) | 2015-12-22 | 2018-10-31 | H. Hoffnabb-La Roche Ag | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS |
| US10435396B2 (en) | 2016-03-03 | 2019-10-08 | Bayer Pharma Aktiegesellschaft | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| US10059708B2 (en) | 2016-04-26 | 2018-08-28 | Northwestern University | Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) |
| WO2017207386A1 (de) | 2016-06-01 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen |
| JP2020524692A (ja) | 2017-06-21 | 2020-08-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Irak4調節因子としてのベンゾフラン |
| CN110785418A (zh) | 2017-06-21 | 2020-02-11 | 豪夫迈·罗氏有限公司 | 作为irak4调节剂的异二氢吲哚酮衍生物 |
| KR20220027196A (ko) | 2019-06-27 | 2022-03-07 | 바이오젠 엠에이 인코포레이티드 | 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도 |
| CN114585609B (zh) | 2019-06-27 | 2024-07-30 | 比奥根Ma公司 | 2h-吲唑衍生物及其在疾病治疗中的用途 |
-
2021
- 2021-12-01 US US17/457,249 patent/US11866405B2/en active Active
- 2021-12-09 SI SI202130206T patent/SI4259632T1/sl unknown
- 2021-12-09 AU AU2021395816A patent/AU2021395816B2/en active Active
- 2021-12-09 DK DK21836097.2T patent/DK4259632T3/da active
- 2021-12-09 UA UAA202303173A patent/UA130417C2/uk unknown
- 2021-12-09 MX MX2023006816A patent/MX2023006816A/es unknown
- 2021-12-09 JP JP2023535016A patent/JP7749015B2/ja active Active
- 2021-12-09 HU HUE21836097A patent/HUE068584T2/hu unknown
- 2021-12-09 CR CR20230264A patent/CR20230264A/es unknown
- 2021-12-09 SM SM20240417T patent/SMT202400417T1/it unknown
- 2021-12-09 FI FIEP21836097.2T patent/FI4259632T3/fi active
- 2021-12-09 HR HRP20241312TT patent/HRP20241312T1/hr unknown
- 2021-12-09 RS RS20241183A patent/RS66095B1/sr unknown
- 2021-12-09 LT LTEPPCT/EP2021/084916T patent/LT4259632T/lt unknown
- 2021-12-09 CN CN202180082181.5A patent/CN116583285B/zh active Active
- 2021-12-09 PE PE2023001857A patent/PE20240684A1/es unknown
- 2021-12-09 PL PL21836097.2T patent/PL4259632T3/pl unknown
- 2021-12-09 ES ES21836097T patent/ES2989489T3/es active Active
- 2021-12-09 MA MA62535A patent/MA62535B1/fr unknown
- 2021-12-09 WO PCT/EP2021/084916 patent/WO2022122876A1/en not_active Ceased
- 2021-12-09 EP EP21836097.2A patent/EP4259632B1/en active Active
- 2021-12-09 KR KR1020237023107A patent/KR20230118153A/ko active Pending
- 2021-12-09 PT PT218360972T patent/PT4259632T/pt unknown
- 2021-12-09 CA CA3203569A patent/CA3203569A1/en active Pending
- 2021-12-09 TW TW110145977A patent/TWI902994B/zh active
- 2021-12-10 AR ARP210103432A patent/AR124303A1/es unknown
- 2021-12-10 UY UY0001039561A patent/UY39561A/es unknown
-
2023
- 2023-05-31 IL IL303356A patent/IL303356B2/en unknown
- 2023-06-08 CL CL2023001662A patent/CL2023001662A1/es unknown
- 2023-06-09 CO CONC2023/0007624A patent/CO2023007624A2/es unknown
- 2023-06-09 DO DO2023000119A patent/DOP2023000119A/es unknown
- 2023-07-05 EC ECSENADI202350553A patent/ECSP23050553A/es unknown
- 2023-07-05 ZA ZA2023/06848A patent/ZA202306848B/en unknown
- 2023-11-02 US US18/500,155 patent/US12448385B2/en active Active
-
2025
- 2025-09-29 US US19/343,252 patent/US20260092069A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781571B1 (en) | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) | |
| EP2520577B1 (en) | Pyrazolo[1,5-a]pyrimidine compounds as cb1 receptor antagonists | |
| JP7292271B2 (ja) | 炎症性障害の治療のための新規化合物及びその医薬組成物 | |
| JP6467404B2 (ja) | P2x7モジュレーター | |
| JP2021522206A5 (cg-RX-API-DMAC7.html) | ||
| JP2013502396A5 (cg-RX-API-DMAC7.html) | ||
| HRP20120824T1 (hr) | Derivati 4-(3-aminopirazol) pirimidina za uporabu kao inhibitori tirozin kinaze u lijeäśenju karcinoma | |
| JP2015527401A5 (cg-RX-API-DMAC7.html) | ||
| CA2917050A1 (en) | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | |
| JP2017511365A5 (cg-RX-API-DMAC7.html) | ||
| NZ606848A (en) | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
| JP2013533868A (ja) | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 | |
| MXPA03009938A (es) | Pirimidinas fusionadas como antagonistas del factor liberador de corticotropina. | |
| JP2019504901A5 (cg-RX-API-DMAC7.html) | ||
| EP3694858B1 (en) | Bicyclic compounds for use as rip1 kinase inhibitors | |
| JP2018522034A5 (cg-RX-API-DMAC7.html) | ||
| MX2013003913A (es) | Compuestos de furo [3, 2-d] pirimidina. | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| EP3548484A1 (en) | Bicyclic amide compounds and methods of use thereof | |
| EP4161656A1 (en) | Inhibitors of fibroblast growth factor receptor kinases | |
| HRP20241312T1 (hr) | Derivati n-(imidazo[1,2-b]piridazin-3-il)-1-cikloheksil-2h-indazol-5-karboksamida i n-(pirazolo[1,5-a]pirimidin-3-il)-1-cikloheksil-2h-indazol-5-karboksamida kao inhibitori irak4 za liječenje astme | |
| JP2023527827A (ja) | Il-17aモジュレーター | |
| RU2009103300A (ru) | Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии | |
| KR20250145089A (ko) | 이미다조트리아진 il-17a 조정제 및 그의 용도 | |
| JP2014528436A5 (cg-RX-API-DMAC7.html) |